Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:APLS)

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire 1 day ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 4, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 1, 2024

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

GlobeNewswire March 11, 2024

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2024

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 27, 2024

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire February 26, 2024

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Accesswire February 20, 2024

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 20, 2024
View More News ››

Opinion & Analysis (NDAQ:APLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APLS)

If You Invested $1000 In This Stock 5 Years Ago, You Would H

Breaking News: $APLS If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today | BenzingaApellis Pharmaceuticals...
whytestocks - April 10, 2024

$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would

Breaking News: $APLS $1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today | BenzingaApellis...
whytestocks - February 5, 2024
View more Bullboard ››

Numinus Wellness Inc

Numinus Wellness Inc

Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the ...
View More »